- 2.7Impact Factor
- 4.5CiteScore
- 23 daysTime to First Decision
Special Issues
Antibodies publishes Special Issues to create collections of papers on specific topics, with the aim of building a community of authors and readers to discuss the latest research and develop new ideas and research directions. Special Issues are led by Guest Editors, who are experts on the topic and all Special Issue submissions follow MDPI's standard editorial process.
The journal’s Editor-in-Chief and/or designated Editorial Board Member will oversee Guest Editor appointments and Special Issue proposals, checking their content for relevance and ensuring the suitability of the material for the journal. The papers published in a Special Issue will be collected and displayed on a dedicated page of the journal’s website. Further information on MDPI's Special Issue polices and Guest Editor responsibilities can be found here. For any inquiries related to a Special Issue, please contact the Editorial Office.
A Festschrift Celebrating Dr. Dimiter Stanchev Dimitrov: Antibodies, Innovation, and Impact on Infectious Disease and Cancer Research
Deadline: 30 June 2026
Antibody and Autoantibody Specificities in Autoimmunity
Deadline: 30 June 2026
Antibody-Mediated Rejection in Kidney Transplantation
Deadline: 25 June 2026
Antiphospholipid Antibodies: Beyond Biomarkers
Deadline: 25 May 2026
Selected Papers from The 1st International Online Conference by Antibodies 2025
Deadline: 28 February 2026
Recombinant Binding Proteins and Genetically Engineered T-cells Targeting Intracellular Neoantigens
Deadline: 25 February 2026
Therapeutic Antibodies: New Trends in Discovery, Developability and Characterization
Deadline: 15 December 2025
Antiviral Antibody Immune Responses in the Context of Vaccination and Infection
Deadline: 15 December 2025
Emerging Antibody Engineering Strategies and Applications for Immunotherapy of Cancer
Deadline: 20 September 2025
Novel Strategies and Technologies for the Development of Tumor-Specific Antibodies
Deadline: 30 June 2024
Autoimmune and Inflammatory Rheumatic Diseases: Potential Biomarkers, Antibodies Response and New Therapies
Deadline: 30 April 2024
SARS-CoV-2: Immune Response Elicited by Infection or Vaccination
Deadline: 28 February 2024
of 4

